Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00320918 · ClinicalTrials.gov registry record

Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib

A clinical trial, sponsored by University of New Mexico.

Terminated
Registry status
10
Enrollment target

NCT00320918: Clinical Trial study, sponsored by University of New Mexico.

NCT00320918 is a clinical trial that was terminated before completion, run by University of New Mexico. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00320918 was terminated before completion, sponsored by University of New Mexico.

TERMINATED
Registry status
10 participants
Enrollment target

Study Summary

Chart Review on Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer Center with a combination of irinotecan, capecitabine and celecoxib.

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2005-11
Est. Completion 2006-10
University of New Mexico

168 total trials

Why NCT00320918 stopped before completion

NCT00320918 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT00320918 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00320918 about?

NCT00320918 is a clinical study titled "Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib". Chart Review on Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer Center with a combination of irinotecan, capecitabine and celecoxib.

What is the current status of trial NCT00320918?

This trial is currently terminated. The enrollment target is 10 participants. The study started on 2005-11. Estimated completion is 2006-10.

Who is sponsoring clinical trial NCT00320918?

This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00320918, the US trial registry maintained by the National Library of Medicine. NCT00320918 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.